Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.000
Neutral
RSI(14)
46.828
Neutral
STOCH(KDJ)(9,3,3)
70.299
Neutral
ATR(14)
0.005
High Vlolatility
CCI(14)
-2.066
Neutral
Williams %R
41.176
Buy
TRIX(12,20)
-0.301
Sell
StochRSI(14)
0.000
Sell
CERo Therapeutics Holdings Inc
CEROWView Detailed Chart
0.010USD
-0.002-21.26%
Close 04/23, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-21.26%
5 Days
-19.35%
1 Month
-13.79%
6 Months
+85.19%
Year to Date
+20.48%
1 Year
-88.95%
View Detailed Chart
Agency Rating
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Sell
Moving Average
Indicators
Value
Direction
MA5
0.014
Sell
MA10
0.012
Sell
MA20
0.013
Sell
MA50
0.013
Sell
MA100
0.013
Sell
MA200
0.012
Sell
News
More news coming soon, stay tuned...
Company
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
Company codeCEROW
CompanyCERo Therapeutics Holdings Inc
CEOMr. Christopher B. (Chris) Ehrlich
Websitehttps://www.phoenixbiotechacquisitioncorp.com/
